A phase 1/2, Multicenter, Open-Label, Dose-escalation and expansion, Safety, Pharmacokinetic, Pharmacodynamic, and clinical activity study of orally administered AG-221 in subjects with advanced hematologic malignancies with an IDH2 mutation. Here, IDH2 is linked to hematologic disorder.